Press Releases

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating

NEW YORK--(BUSINESS WIRE)-- As Drive Shack Inc. (“Drive Shack” or the “Company”) continues to transform into a leading golf and entertainment company, the Board of Directors is excited to announce the addition of Ken May and David Hammarley to the management team to further drive the growth of the business. Ken May, who joins the Company as Chief Executive Officer and President, was most

KIYOSU, Japan--(BUSINESS WIRE)-- Toyoda Gosei Co., Ltd. will establish a Corporate Venture Capital Department in January 2019. This new department will serve as the company’s center for flexible and swift investment in startups and venture capital to accelerate open innovations for practical application and commercialization of new technologies and products. Toyoda Gosei formulated its medium a

BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy and peanut allergy at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 15-19, 2018, in Seattle. AR101 i

NEW YORK--(BUSINESS WIRE)-- Today, Drive Shack Inc. (NYSE: DS), formally announced plans to open a new golf entertainment and recreation complex in Manhattan, after New York City Department of Parks and Recreation (“NYC Parks”) officials awarded the Company a site at Randall’s Island Park. Drive Shack will completely rebuild and replace the existing golf driving range with a year-round golf-ce

PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the third quarter ended September 30, 2018. “During the third quarter of 2018, we continued to advance inclisiran through Phase III trials and other, key development steps,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We continue t

CHARLOTTE, N.C.--(BUSINESS WIRE)-- RumbleOn, Inc. (NASDAQ:RMBL), the only 100-percent-online powersports and pre-owned vehicle marketplace, today announced senior management will address the investment community at the following conferences: Southwest IDEAS Investor ConferenceDate: Tuesday, Nov. 14, 2018Time: 3:50 p.m. CTFormat: Presentation* and 1x1 meetingsLocation: Fairmont Hotel,

BATAVIA, N.Y.--(BUSINESS WIRE)-- Graham Corporation (NYSE:GHM), a global business that designs, manufactures and sells critical equipment for the oil refining, petrochemical, power and defense industries, today reported financial results for its second quarter and six months ended September 30, 2018. Graham’s current fiscal year ends March 31, 2019 (

WALTHAM, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the third quarter ended September 30, 2018. “We have made substantial progress over the

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Liberty Media Corporation ("Liberty Media" or “Liberty”) (NASDAQ: LSXMA, LSXMB, LSXMK, FWONA, FWONK, BATRA, BATRK) today reported third quarter 2018 results. Highlights include(1): Attributed to Liberty SiriusXM Group SiriusXM reported strong third quarte

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time to discuss this announcement and answer questions. “This quarter was marked b

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target immune drivers of cancer and other immune-related disorders, today announced that data from a Phase 1 study of FLX475 in healthy volunteers which demonstrated excellent pharmacokinetics, pharmacodynamics, and safety and tolerability will be

SAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced that the Company will release its September 30, 2018 third quarter financial results on Wednesday, November 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recen

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that management will present a company update at the Jefferies 2018 London Healthcare Conference. The presentation will take place at 5:20 p.m. GMT on Thursday, November 15, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power